Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease

Molecular Psychiatry

Volumn 20, Issue 11, 2015, Pages 1294-1300

  Lalli, M A ^a   Bettcher, B M ^b   Arcila, M L ^a   Garcia, G ^c   Guzman, C ^c   Madrigal, L ^c   Ramirez, L ^c   Acosta Uribe, J ^c   Baena, A ^c   Wojta, K J ^d   Coppola, G ^d   Fitch, R ^b   De Both, M D ^e   Huentelman, M J ^e   Reiman, E M ^e,f   Brunkow, M E ^g   Glusman, G ^g   Roach, J C ^g   Kao, A W ^b   Lopera, F ^c   Kosik, K S ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^g INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; EOTAXIN; PRESENILIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHROMOSOME 17; CONTROLLED STUDY; CYTOKINE RELEASE; DEMENTIA; FAMILIAL DISEASE; FEMALE; GENE CLUSTER; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; ONSET AGE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; MIDDLE AGED;

ADULT; AGE OF ONSET; AGED; ALZHEIMER DISEASE; CHEMOKINE CCL11; CHROMOSOMES, HUMAN, PAIR 17; COGNITION DISORDERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84946492477     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.131     Document Type: Article

References (48)

1. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: A retrospective cohort study. Lancet Neurol 2011; 10: 213-220.
2. Li YJ, Scott WK, Hedges DJ, Zhang FY, Gaskell PC, Nance MA et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002; 70: 985-993.
3. Pedersen NL, Posner SF, Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet 2001; 105: 724-728.
4. Marchani EE, Bird TD, Steinbart EJ, Rosenthal E, Yu CE, Schellenberg GD et al. Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families. Am J Med Genet B 2010; 153B: 1031-1041.
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
6. Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, Garcia G et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 2003; 54: 163-169.
7. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997; 277: 793-799.
8. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 1: 388-405.
9. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
10. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
11. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
12. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-116.
13. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 2014; 34: 11929-11947.
14. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999; 22: 219-240.
15. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25-34.
16. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705.
17. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009; 19: 392-398.
18. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012; 7: 30.
19. Lalli MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. Alzheimers Dement 2013; 13: 02840-02849.
20. Visscher PM, Andrew T, Nyholt DR. Genome-wide association studies of quantitative traits with related individuals: little (power) lost but much to be gained. Eur J Hum Genet 2008; 16: 387-390.
21. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
22. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
23. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
24. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18 F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010; 51: 913-920.
25. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010; 327: 78-81.
26. Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010; 328: 636-639.
27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
28. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008; 32: 227-234.
29. Lange K, Papp JC, Sinsheimer JS, Sripracha R, Zhou H, Sobel EM. Mendel: The Swiss army knife of genetic analysis programs. Bioinformatics 2013; 29: 1568-1570.
30. Lalli MA, Garcia G, Madrigal L, Arcos-Burgos M, Arcila ML, Kosik KS et al. Exploratory data from complete genomes of familial Alzheimer disease age-atonset outliers. Hum Mutat 2012; 33: 1630-1634.
31. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: 3.
32. Glusman G, Caballero J, Mauldin DE, Hood L, Roach JC. Kaviar: an accessible system for testing SNV novelty. Bioinformatics 2011; 27: 3216-3217.
33. Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe S, Thomas N et al. Human gene mutation database-A biomedical information and research resource. Hum Mutat 2000; 15: 45-51.
34. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814.
35. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014; 46: 310-315.
36. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 1997; 51: 135-138.
37. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224: 93-100.
38. Luo Y, Laning J, Devi S, Mak J, Schall TJ, Dorf ME. Biologic activities of the murine beta-chemokine TCA3. J Immunol 1994; 153: 4616-4624.
39. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477: 90-94.
40. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011; 8: 785-786.
41. Haga SB. Impact of limited population diversity of genome-wide association studies. Genet Med 2010; 12: 81-84.
42. Wang J, Asensio VC, Campbell IL. Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. Curr Top Microbiol Immunol 2002; 265: 23-48.
43. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997; 16: 6996-7007.
44. Millard CJ, Ludeman JP, Canals M, Bridgford JL, Hinds MG, Clayton DJ et al. Structural basis of receptor sulfotyrosine recognition by a CC chemokine: The N-terminal region of CCR3 bound to CCL11/eotaxin-1. Structure 2014; 22: 1571-1581.
45. Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 2010; 24: 3093-3102.
46. Kawahara K, Suenobu M, Yoshida A, Koga K, Hyodo A, Ohtsuka H et al. Intracerebral microinjection of interleukin-4/interleukin-13 reduces beta-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice. Neuroscience 2012; 207: 243-260.
47. Moore PE, Church TL, Chism DD, Panettieri RA Jr, Shore SA. IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: A role for ERK. Am J Physiol Lung Cell Mol Physiol 2002; 282: L847-L853.
48. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD et al. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol 2002; 59: 1737-1746.